tetano
Editor, Senior Moderator
Viral Immunol
. 2022 Oct 6.
doi: 10.1089/vim.2021.0160. Online ahead of print.
Antibody Therapy for COVID-19: Categories, Pros, and Cons
Hadi Zare Marzouni[SUP] 1 [/SUP], Marjan Rahbar[SUP] 2 [/SUP], Nazanin Seddighi[SUP] 1 [/SUP], Mohsen Nabizadeh[SUP] 3 [/SUP], Sepideh Meidaninikjeh[SUP] 4 5 [/SUP], Nasim Sabouni[SUP] 6 [/SUP]
Affiliations
Abstract
COVID-19 is a life-threatening respiratory disease triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has been considered a pandemic viral infection since December 2019. The investigation of the effective prophylaxis or therapeutic strategies for emergency management of the current condition has become a priority for medical research centers and pharmaceutical companies. This article provides a comprehensive review of antibody therapy and its different categories with their advantages and disadvantages for COVID-19 over the last few years of the current pandemic. Antibodies can be generated by active immunization, including natural infection with a pathogen and vaccination, or by the passive immunization method such as convalescent plasma therapy (CPT) and antibody synthesis in laboratories. Each of these ways has its characteristics. Arming the immune system with antibodies is the main aim of antiviral therapeutic procedures toward SARS-CoV-2. Collecting and discussing various aspects of available data in this field can give researchers a better perspective for the production of antibody-based products or selection of the most appropriate approach of antibody therapies to improve different cases of COVID-19. Moreover, it can help them control similar viral pandemics that may happen in the future appropriately.
Keywords: COVID-19; SARS-CoV-2; antibodies; immunity; therapy.
. 2022 Oct 6.
doi: 10.1089/vim.2021.0160. Online ahead of print.
Antibody Therapy for COVID-19: Categories, Pros, and Cons
Hadi Zare Marzouni[SUP] 1 [/SUP], Marjan Rahbar[SUP] 2 [/SUP], Nazanin Seddighi[SUP] 1 [/SUP], Mohsen Nabizadeh[SUP] 3 [/SUP], Sepideh Meidaninikjeh[SUP] 4 5 [/SUP], Nasim Sabouni[SUP] 6 [/SUP]
Affiliations
- PMID: 36201297
- DOI: 10.1089/vim.2021.0160
Abstract
COVID-19 is a life-threatening respiratory disease triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has been considered a pandemic viral infection since December 2019. The investigation of the effective prophylaxis or therapeutic strategies for emergency management of the current condition has become a priority for medical research centers and pharmaceutical companies. This article provides a comprehensive review of antibody therapy and its different categories with their advantages and disadvantages for COVID-19 over the last few years of the current pandemic. Antibodies can be generated by active immunization, including natural infection with a pathogen and vaccination, or by the passive immunization method such as convalescent plasma therapy (CPT) and antibody synthesis in laboratories. Each of these ways has its characteristics. Arming the immune system with antibodies is the main aim of antiviral therapeutic procedures toward SARS-CoV-2. Collecting and discussing various aspects of available data in this field can give researchers a better perspective for the production of antibody-based products or selection of the most appropriate approach of antibody therapies to improve different cases of COVID-19. Moreover, it can help them control similar viral pandemics that may happen in the future appropriately.
Keywords: COVID-19; SARS-CoV-2; antibodies; immunity; therapy.